Stemline Therapeutics Inc (STML) Insider David Gionco Sells 4,250 Shares

Stemline Therapeutics Inc (NASDAQ:STML) insider David Gionco sold 4,250 shares of the firm’s stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $13.43, for a total value of $57,077.50. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of Stemline Therapeutics Inc (NASDAQ STML) traded down $0.35 on Friday, reaching $15.70. The company’s stock had a trading volume of 341,336 shares, compared to its average volume of 390,180. Stemline Therapeutics Inc has a 52-week low of $6.35 and a 52-week high of $17.40.

Stemline Therapeutics (NASDAQ:STML) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.11). The company had revenue of $0.30 million for the quarter, compared to analyst estimates of $0.30 million. Stemline Therapeutics had a negative return on equity of 75.50% and a negative net margin of 4,689.63%. equities analysts anticipate that Stemline Therapeutics Inc will post -2.68 earnings per share for the current fiscal year.

Several equities research analysts recently weighed in on STML shares. Cowen reissued a “buy” rating on shares of Stemline Therapeutics in a report on Tuesday, October 31st. HC Wainwright raised their price objective on Stemline Therapeutics from $34.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, November 1st. BidaskClub downgraded Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 22nd. ValuEngine raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Finally, Zacks Investment Research raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, January 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $33.75.

Institutional investors and hedge funds have recently made changes to their positions in the business. Teachers Advisors LLC lifted its stake in shares of Stemline Therapeutics by 1.3% in the 2nd quarter. Teachers Advisors LLC now owns 43,397 shares of the biopharmaceutical company’s stock valued at $399,000 after purchasing an additional 541 shares during the period. Nationwide Fund Advisors lifted its stake in shares of Stemline Therapeutics by 7.2% in the 2nd quarter. Nationwide Fund Advisors now owns 12,755 shares of the biopharmaceutical company’s stock valued at $117,000 after purchasing an additional 855 shares during the period. Rhumbline Advisers lifted its stake in shares of Stemline Therapeutics by 18.5% in the 2nd quarter. Rhumbline Advisers now owns 27,358 shares of the biopharmaceutical company’s stock valued at $252,000 after purchasing an additional 4,280 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Stemline Therapeutics by 40.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,279 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 5,522 shares during the period. Finally, Royce & Associates LP acquired a new position in shares of Stemline Therapeutics in the 4th quarter valued at about $106,000. 43.87% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://stocknewstimes.com/2018/02/11/david-gionco-sells-4250-shares-of-stemline-therapeutics-inc-stml-stock.html.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply